Compare NRG Energy Inc (NRG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? NRG Energy Inc trades at $99.84 (market cap $22.53B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: NRG Energy Inc is far larger — about 4.6× Travere Therapeutics Inc. Common Stock's market cap, and NRG Energy Inc pays a 1.77% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NRG | TVTX | |
|---|---|---|
Market Cap | $22.53B | $4.88B |
Volume | 2,965,287 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $184.03 | $67.52 |
52-Week Low | $95.23 | $26.79 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $46.49B | $5.01B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $100.85, down 5.19% on the day amid mixed earnings results, with recent Q1 and Q2 2026 EPS misses. The stock shows neutral technical signals with bearish moving averages, while fundamentals reflect strong revenue growth to $30.71B in 2025 and a solid ROE of 26.77%, though net margins are thin at 2.56%. Recent news highlights a major 1.2 GW Texas data-center power project as a growth driver.
Outlook is cautiously optimistic given analyst consensus favoring Buy (70.37%) and a $202.90 price target, implying significant upside. Key risks include execution on large capex projects, rising debt-to-asset ratio (56.42% in 2025), and competitive pressures in utilities. The stock offers value with a low P/S of 0.66 but requires monitoring of earnings consistency and leverage trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
